Atlas Trials

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

Clinical trial NCT03283137 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03283137
Sponsor
University of Chicago
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
CLLB-cell Non Hodgkin Lymphoma
Start date
2018-01-23
Primary completion
2027-12-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.